Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies (PTN)
XASE:PTN
PTN Stock Chart & Stats
$16.05
--
Market closed
$16.05
--
Day’s Range― - ―
52-Week Range$1.77 - $45.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.99K
Market Cap
$36.70M
Enterprise Value$554.36M
Total Cash (Recent Filing)$14.48M
Total Debt (Recent Filing)$348.79K
Price to Earnings (P/E)―
Beta-0.33
Next Earnings
May 19, 2026EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.86
Shares Outstanding1,772,199
10 Day Avg. Volume2,746
30 Day Avg. Volume2,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.18
Enterprise Value/Market Cap15.10
Enterprise Value/Revenue61.85
Enterprise Value/Gross Profit62.31
Enterprise Value/Ebitda-57.96
Forecast
1Y Price Target
$50.00Price Target Upside211.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.45
Revenue Forecast (FY)$9.68M
Bulls Say, Bears Say
Bulls Say
High Gross-margin Licensing ModelPalatin’s revenue mix (royalties, milestones, licensing) generates very high gross margins, a durable structural advantage versus product-centric peers. High gross margin preserves incremental economics as revenue scales, improving ability to fund R&D per dollar of revenue over the next 2–6 months.
Very Low Financial LeverageMinimal debt reduces near-term solvency and interest burdens, giving management flexibility to prioritize development spending or partnership deals. Low leverage materially lowers bankruptcy risk and preserves options for non-dilutive funding over the medium term.
Strengthened Liquidity To Fund Phase I PlansThe recent $18.2M offering and cash balance materially de‑risk near-term execution, enabling IND submissions and Phase I SAD/MAD for two MC4R programs. Having funded Phase I work reduces short‑term financing pressure and increases probability of hitting development milestones.
Bears Say
Persistent Negative Cash FlowSustained multi‑year cash burn means the business cannot self‑fund development beyond current runway, forcing reliance on equity, warrants, or partner milestone payments. That structural cash deficit increases dilution risk and constrains strategic optionality over the next several quarters.
Unstable Equity / Past Accumulated LossesNegative and volatile shareholders’ equity reflects accumulated losses and prior financing; this can limit access to traditional credit, push future capital to dilutive equity, and weaken bargaining power in collaborations, affecting funding cost and flexibility over the medium term.
Clinical Differentiation And Market CompetitionPalatin targets differentiated MC4R programs in a crowded obesity/weight‑loss landscape where GLP‑1s dominate. Durable commercial success requires clear safety/tolerability and differentiation; failure to show this in trials would limit partner interest and royalty potential, a structural industry risk.
Palatin Technologies News
PTN FAQ
What was Palatin Technologies’s price range in the past 12 months?
Palatin Technologies lowest stock price was $1.77 and its highest was $45.00 in the past 12 months.
What is Palatin Technologies’s market cap?
Palatin Technologies’s market cap is $36.70M.
When is Palatin Technologies’s upcoming earnings report date?
Palatin Technologies’s upcoming earnings report date is May 19, 2026 which is in 75 days.
How were Palatin Technologies’s earnings last quarter?
Palatin Technologies released its earnings results on Feb 17, 2026. The company reported -$2.86 earnings per share for the quarter, missing the consensus estimate of -$2.353 by -$0.507.
Is Palatin Technologies overvalued?
According to Wall Street analysts Palatin Technologies’s price is currently Undervalued.
Does Palatin Technologies pay dividends?
Palatin Technologies does not currently pay dividends.
What is Palatin Technologies’s EPS estimate?
Palatin Technologies’s EPS estimate is -1.24.
How many shares outstanding does Palatin Technologies have?
Palatin Technologies has 1,772,199 shares outstanding.
What happened to Palatin Technologies’s price movement after its last earnings report?
Palatin Technologies reported an EPS of -$2.86 in its last earnings report, missing expectations of -$2.353. Following the earnings report the stock price went up 1.15%.
Which hedge fund is a major shareholder of Palatin Technologies?
Currently, no hedge funds are holding shares in PTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
PTN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted substantial strategic and financial progress: a successful $18.2M public offering (net $16.9M), regained NYSE American listing, a $14.5M cash balance with a runway beyond March 31, 2027, and clear IND/Phase I timelines for two MC4R programs with sufficient cash to execute Phase I. Offsetting these positives are materially higher operating expenses and a larger net loss versus the prior year, minimal current commercial revenue, a decline in other income, and remaining uncertainties around warrant exercises and clinical differentiation. On balance, the financing and clear development milestones materially de-risk near-term execution, while the company still faces typical biotech development and competitive risks.View all PTN earnings summariesPTN Stock 12 Month Forecast
Average Price Target
$50.00
▲(211.53% Upside)
Technical Analysis
Ibio
―
Phio Pharmaceuticals
―
BioRestorative Therapies
―
Addex Therapeutics
―
Bolt Biotherapeutics
―